Prussian Blue Nanozyme Promotes the Survival Rate of Skin Flaps by Maintaining a Normal Microenvironment
Rui Hou1, Tianxiang Lu2, Wei Gao3
1Department of Plastic and Reconstructive Surgery, The Ninth People'S Hospital Affiliated To Shanghai Jiao Tong University School Of medicine, Shanghai, 200011, People's Republic of China.
Abstract:
Ischemia-reperfusion (I/R) injury leads to a low success rate of skin flap transplantation in reconstruction surgery, thus requiring development of new treatments. Necroptosis and apoptosis pathways, along with overexpression of reactive oxygen species and pro-inflammatory factors in skin flap transplantation, are deemed as potential therapeutic targets. This study provides a paradigm for nanozyme-mediated microenvironment maintenance to improve the survival rate of the transplanted skin flap. Prussian blue nanozyme (PBzyme) with multiple intrinsic biological activities was constructed and selected for this proof-of-concept study. The prepared PBzyme shows anti-inflammatory, antiapoptotic, antinecroptotic, and antioxidant activities in both in vitro and in vivo models of I/R injured skin flaps. The multiple inhibitory effects of PBzyme maintained a normal microenvironment and thus significantly promoted the survival rate of the I/R injured skin flap (from 37.21 ± 8.205% to 79.61 ± 7.5%). Of note, PBzyme regulated the expression of the characteristic signal molecules of necroptosis, including Rip 1, Rip 3, and pMLKL, indicating that PBzyme may be a therapeutic agent for necroptosis-related diseases. This study shows great prospects for clinical application of PBzyme in the treatment of skin flaps via local administration.
Insights
Prussian blue nanozyme (PBzyme) effectively treats skin flap transplantation by reducing inflammation, apoptosis, and oxidative stress. This nanozyme significantly improves skin flap survival rates, offering a promising therapeutic approach for related diseases.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Nanotechnology
Background:
- Ischemia-reperfusion (I/R) injury compromises skin flap transplantation success.
- Necroptosis, apoptosis, reactive oxygen species, and inflammation are key pathological factors in I/R injury.
- Novel therapeutic strategies are needed to enhance skin flap survival.
Purpose of the Study:
- To develop a nanozyme-mediated strategy for microenvironment maintenance in skin flap transplantation.
- To investigate the therapeutic potential of Prussian blue nanozyme (PBzyme) in improving I/R injured skin flap survival.
Main Methods:
- Construction and characterization of Prussian blue nanozyme (PBzyme).
- In vitro and in vivo evaluation of PBzyme's anti-inflammatory, antiapoptotic, antinecroptotic, and antioxidant activities.
- Assessment of PBzyme's effect on skin flap survival rate and necroptosis-related signaling molecules (Rip 1, Rip 3, pMLKL).
Main Results:
- PBzyme demonstrated significant anti-inflammatory, antiapoptotic, antinecroptotic, and antioxidant properties.
- PBzyme treatment increased I/R injured skin flap survival rate from 37.21 ± 8.205% to 79.61 ± 7.5%.
- PBzyme modulated the expression of necroptosis markers, suggesting a role in regulating this cell death pathway.
Conclusions:
- PBzyme effectively maintains a favorable microenvironment for skin flap survival by mitigating I/R injury.
- PBzyme shows promise as a therapeutic agent for necroptosis-related diseases and skin flap transplantation.
- Local administration of PBzyme holds significant potential for clinical application in reconstructive surgery.
Related Concept Videos
01:12Renewal of Skin Epidermal Stem Cells
01:19Clinical Applications of Epidermal Stem Cells